BMY - Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
2024-05-30 12:22:21 ET
More on Bristol-Myers Squibb Company
- Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
- Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
- Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
- Bristol-Myers gets EU approval for Opdivo for bladder cancer
- Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo